ZNF772 expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 1.480840E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
8.469000E-01
Normal-vs-Stage2
6.290400E-02
Normal-vs-Stage3
5.806000E-02
Normal-vs-Stage4
8.943200E-01
Stage1-vs-Stage2
1.998020E-01
Stage1-vs-Stage3
7.600500E-02
Stage1-vs-Stage4
7.594600E-01
Stage2-vs-Stage3
2.79679612802397E-11
Stage2-vs-Stage4
6.365600E-02
Stage3-vs-Stage4
1.101960E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
1.674780E-01
Normal-vs-AfricanAmerican
1.913010E-01
Normal-vs-Asian
1.353210E-01
Caucasian-vs-AfricanAmerican
8.415200E-01
Caucasian-vs-Asian
5.197600E-01
AfricanAmerican-vs-Asian
8.174200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
1.034800E-01
Normal-vs-Female
2.243400E-01
Male-vs-Female
4.426400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
7.642200E-01
Normal-vs-Age(41-60Yrs)
2.865600E-01
Normal-vs-Age(61-80Yrs)
9.353900E-02
Normal-vs-Age(81-100Yrs)
5.198300E-03
Age(21-40Yrs)-vs-Age(41-60Yrs)
5.363000E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
4.198600E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
3.698200E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
1.788150E-02
Age(41-60Yrs)-vs-Age(81-100Yrs)
5.283200E-03
Age(61-80Yrs)-vs-Age(81-100Yrs)
2.570800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
2.282000E-02
Normal-vs-Daily Drinker
3.324100E-02
Normal-vs-Weekly Drinker
1.322540E-03
Normal-vs-Occasional Drinker
7.521000E-01
Normal-vs-Social Drinker
2.224800E-01
Non Drinker-vs-Daily Drinker
9.261800E-01
Non Drinker-vs-Weekly Drinker
5.408400E-01
Non Drinker-vs-Occasional Drinker
1.643000E-03
Non Drinker-vs-Social Drinker
2.054800E-01
Daily Drinker-vs-Weekly Drinker
5.914000E-01
Daily Drinker-vs-Occasional Drinker
3.915300E-03
Daily Drinker-vs-Social Drinker
2.268600E-01
Weekly Drinker-vs-Occasional Drinker
1.198680E-03
Weekly Drinker-vs-Social Drinker
1.033980E-01
Occasional Drinker-vs-Social Drinker
1.355040E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
2.391200E-01
Normal-vs-Grade 2
1.867190E-01
Normal-vs-Grade 3
1.906970E-01
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
5.236100E-02
Grade 1-vs-Grade 3
1.380210E-01
Grade 1-vs-Grade 4
2.391200E-01
Grade 2-vs-Grade 3
4.323800E-01
Grade 2-vs-Grade 4
1.867190E-01
Grade 3-vs-Grade 4
1.906970E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
3.104300E-02
Normal-vs-NonDiabetic
1.267620E-01
Diabetic-vs-NonDiabetic
2.864000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
3.55499999999953E-05
Normal-vs-NoPancreatitis
1.164640E-01
Pancreatitis-vs-NoPancreatitis
7.81380000036691E-07
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
2.287400E-01
Normal-vs-N1
6.924100E-02
N0-vs-N1
4.799600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
2.424600E-01
Normal-vs-TP53-NonMutant
3.819200E-01
TP53-Mutant-vs-TP53-NonMutant
8.007000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
